Ardelyx (ARDX) announced upcoming data presentations for tenapanor for hyperphosphatemia at the American Society of Nephrology, ASN, Kidney Week 2023 meeting to be held in Philadelphia, PA, November 1-5, 2023. XPHOZAH, discovered and developed by Ardelyx, is an investigational first-in-class phosphate absorption inhibitor. Ardelyx will present four poster presentations highlighting data from two trials in patients with hyperphosphatemia on maintenance dialysis in the U.S. Additionally, the company’s collaboration partner for tenapanor in Japan, Kyowa Kirin (KYKOF), will present key results from two Phase 3 studies of tenapanor in a similar patient population in Japan.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARDX:
- Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
- Citi opens ‘positive catalyst watch’ on Ardelyx into FDA decision
- Biotech Alert: Searches spiking for these stocks today
- Ardelyx shares preliminary data on use of IBSRELA
- Ardelyx announces publication of results from T3MPO-3 trial of tenapanor